NASDAQ : SCLX
Scilex Holding Company — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 1.85 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 13.01M |
| Enterprise Value | 118.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.03M |
| Shares Outstanding | 7.03M |
| Shares Change (YoY) | -37.27% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 4.69% |
| Owned by Institutions (%) | 10.21% |
| Float | 5.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.99 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -105.83% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 110.40% |
| Weighted Average Cost of Capital (WACC) | 13.40% |
| Revenue Per Employee | $929,647 |
| Profits Per Employee | -$13.19M |
| Employee Count | 34 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 4.21 |
Taxes
| Measure | Value |
|---|
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -89.97% |
| 50-Day Moving Average | 4.17 |
| 200-Day Moving Average | 6.87 |
| Relative Strength Index (RSI) | 14.04 |
| Average Volume (20 Days) | 46,524 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 148,382 |
| Short Previous Month | 171,151 |
| Short % of Shares Out | 2.11% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 3.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 31.61M |
| Gross Profit | 17.54M |
| Operating Income | -285.59M |
| Pretax Income | -464.55M |
| Net Income | -448.35M |
| EBITDA | -277.27M |
| EBIT | -285.59M |
| Loss Per Share | -$51.60 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 581,000 |
| Total Debt | 105.99M |
| Net Cash | -105.40M |
| Net Cash Per Share | -$14.98 |
| Equity (Book Value) | -310.49M |
| Book Value Per Share | -43.83 |
| Working Capital | -476.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.09M |
| Capital Expenditures | -726,000 |
| Depreciation & Amortization | 8.32M |
| Net Borrowing | -2.14M |
| Free Cash Flow | -17.81M |
| FCF Per Share | -$2.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 55.50% |
| Operating Margin | -903.52% |
| Pretax Margin | -1,469.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 37.27% |
| Shareholder Yield | 37.27% |
| Earnings Yield | -2,789.19% |
| FCF Yield | -136.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 171.95% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:35 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.72 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |